#METABOLOMICS WORKBENCH RMbeach1053_20221121_093934 DATATRACK_ID:3589 STUDY_ID:ST002354 ANALYSIS_ID:AN003842 PROJECT_ID:PR001511 VERSION 1 CREATED_ON November 22, 2022, 5:53 am #PROJECT PR:PROJECT_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. PR:PROJECT_SUMMARY Comprehensive analysis of the lipidomic changes resulting from feeding with a PR:PROJECT_SUMMARY over EPA analogue alone, and in combination with the NSAID naproxen. PR:INSTITUTE UConn Health PR:DEPARTMENT Center for Molecular Oncology PR:LABORATORY Rosenberg Laboratory PR:LAST_NAME Beach PR:FIRST_NAME Ryan PR:ADDRESS 263 Farmington Avenue, Farmington, Connecticut, 06030, USA PR:EMAIL rbeach@uchc.edu PR:PHONE 860-679-8703 PR:FUNDING_SOURCE NCI PREVENT funding #STUDY ST:STUDY_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. ST:STUDY_SUMMARY Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in ST:STUDY_SUMMARY the United States. Patients with the genetic disorder Familial Adenomatous ST:STUDY_SUMMARY Polyposis (FAP) develop hundreds to thousands of polyps that unless removed by ST:STUDY_SUMMARY prophylactic colectomy will progress to CRC at an early age. Non-steroidal ST:STUDY_SUMMARY anti-inflammatory drugs (NSAIDs) and -3 marine polyunsaturated fatty acids ST:STUDY_SUMMARY (PUFA), such as eicosapentaenoic acid (EPA), have been evaluated for their ST:STUDY_SUMMARY chemopreventive potential in delaying the onset of CRC in high-risk patients. In ST:STUDY_SUMMARY this study, we determined whether the NSAID, naproxen, alone or in combination ST:STUDY_SUMMARY with a chemically-stable form of EPA (TP-252), affects tumor formation in the ST:STUDY_SUMMARY ApcPirc rat model. When compared to control diet, animals fed naproxen or HD ST:STUDY_SUMMARY TP-252 had 66%, and 82% fewer tumors respectively. However, when fed a ST:STUDY_SUMMARY combination of naproxen and HD TP-252, animals exhibited a 95% reduction in ST:STUDY_SUMMARY tumor formation and a 98% reduction in tumor volume, respectively. To elucidate ST:STUDY_SUMMARY potential mechanisms of tumor protection, a comprehensive, targeted lipidomic ST:STUDY_SUMMARY analysis was performed on colonic mucosa to determine changes in eicosanoid ST:STUDY_SUMMARY metabolism. Animals receiving TP-252 alone or in combination with naproxen had ST:STUDY_SUMMARY significantly reduced mucosal levels of pro-inflammatory -6 eicosanoids ST:STUDY_SUMMARY (PGE2, 5-HETE, and 14,15-DiHETrE), along with a simultaneous increase in ST:STUDY_SUMMARY anti-inflammatory EPA-derived -3 eicosanoids. Our colonic mucosal lipidomic ST:STUDY_SUMMARY analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers, ST:STUDY_SUMMARY including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were increased in both ST:STUDY_SUMMARY the tissue and plasma of rats receiving TP-252 and were significantly correlated ST:STUDY_SUMMARY with tumor protection. Further studies with this drug combination should be ST:STUDY_SUMMARY focused on dose optimization and the role of EPA-derived lipid mediators in CRC ST:STUDY_SUMMARY initiation and progression. ST:INSTITUTE UConn Health ST:LAST_NAME Beach ST:FIRST_NAME Ryan ST:ADDRESS 263 Farmington Avenue, Farmington CT 06030 ST:EMAIL rbeach@uchc.edu ST:PHONE 860-679-8703 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 SU:AGE_OR_AGE_RANGE 26 weeks of age SU:WEIGHT_OR_WEIGHT_RANGE 320-460 grams SU:GENDER Male SU:ANIMAL_ANIMAL_SUPPLIER RRRC (University of Missouri) SU:ANIMAL_HOUSING Center for Comparative Medicine UConn SU:ANIMAL_FEED Modified AIN-93G diet from Research Diets SU:ANIMAL_WATER ab libitum #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS 2440 TFA-T1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T1.wiff SUBJECT_SAMPLE_FACTORS 2443 TFA-T2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T2.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-T3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T3.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-T4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T4.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-T5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T5.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-T6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T6.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-T7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T7.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-T8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T8.wiff SUBJECT_SAMPLE_FACTORS 2446 TFA-T9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T9.wiff SUBJECT_SAMPLE_FACTORS 2336 TFA-T10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T10.wiff SUBJECT_SAMPLE_FACTORS 2850 TFA-T11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T11.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T12.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T13.wiff SUBJECT_SAMPLE_FACTORS 3099 TFA-T14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T14.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-T15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T15.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-T16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T16.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-T17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T17.wiff SUBJECT_SAMPLE_FACTORS 2901 TFA-T18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T18.wiff SUBJECT_SAMPLE_FACTORS 2903 TFA-T19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T19.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-T20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T20.wiff SUBJECT_SAMPLE_FACTORS 3021 TFA-T21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T21.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-T22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T22.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-T23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T23.wiff SUBJECT_SAMPLE_FACTORS 2454 TFA-T24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T24.wiff SUBJECT_SAMPLE_FACTORS 2884 TFA-T25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T25.wiff SUBJECT_SAMPLE_FACTORS 2885 TFA-T26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T26.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-T27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-T28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-T29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-T30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T30.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-T31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T31.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-T32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T32.wiff SUBJECT_SAMPLE_FACTORS 2878 TFA-T33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T33.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-T34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T34.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-T35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T35.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-T36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T36.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-T37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T37.wiff SUBJECT_SAMPLE_FACTORS 2747 TFA-T38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T38.wiff SUBJECT_SAMPLE_FACTORS 2899 TFA-T39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T39.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-T40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T40.wiff SUBJECT_SAMPLE_FACTORS 3029 TFA-T41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T41.wiff SUBJECT_SAMPLE_FACTORS 3030 TFA-T42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T42.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-T43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T43.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-T44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T44.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-T45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T45.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-T46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T46.wiff SUBJECT_SAMPLE_FACTORS 2854 TFA-T47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T47.wiff SUBJECT_SAMPLE_FACTORS 3024 TFA-T48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T48.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-T49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T49.wiff SUBJECT_SAMPLE_FACTORS 3102 TFA-T50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T50.wiff SUBJECT_SAMPLE_FACTORS 3104 TFA-T51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T51.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-T52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T52.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-T53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T53.wiff SUBJECT_SAMPLE_FACTORS 2844 TFA-T54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T54.wiff SUBJECT_SAMPLE_FACTORS 2845 TFA-T55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T55.wiff SUBJECT_SAMPLE_FACTORS 2846 TFA-T56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T56.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoT1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT1.wiff SUBJECT_SAMPLE_FACTORS 2443 EicoT2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT2.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoT3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT3.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoT4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT4.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoT5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT5.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoT6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT6.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoT7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT7.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoT8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT8.wiff SUBJECT_SAMPLE_FACTORS 2446 EicoT9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT9.wiff SUBJECT_SAMPLE_FACTORS 2336 EicoT10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT10.wiff SUBJECT_SAMPLE_FACTORS 2850 EicoT11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT11.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT12.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT13.wiff SUBJECT_SAMPLE_FACTORS 3099 EicoT14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT14.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoT15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT15.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoT16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT16.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoT17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT17.wiff SUBJECT_SAMPLE_FACTORS 2901 EicoT18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT18.wiff SUBJECT_SAMPLE_FACTORS 2903 EicoT19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT19.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoT20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT20.wiff SUBJECT_SAMPLE_FACTORS 3021 EicoT21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT21.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoT22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT22.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoT23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT23.wiff SUBJECT_SAMPLE_FACTORS 2454 EicoT24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT24.wiff SUBJECT_SAMPLE_FACTORS 2884 EicoT25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT25.wiff SUBJECT_SAMPLE_FACTORS 2885 EicoT26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT26.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoT27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoT28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoT29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoT30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT30.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoT31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT31.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoT32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT32.wiff SUBJECT_SAMPLE_FACTORS 2878 EicoT33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT33.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoT34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT34.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoT35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT35.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoT36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT36.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoT37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT37.wiff SUBJECT_SAMPLE_FACTORS 2747 EicoT38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT38.wiff SUBJECT_SAMPLE_FACTORS 2899 EicoT39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT39.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoT40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT40.wiff SUBJECT_SAMPLE_FACTORS 3029 EicoT41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT41.wiff SUBJECT_SAMPLE_FACTORS 3030 EicoT42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT42.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoT43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT43.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoT44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT44.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoT45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT45.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoT46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT46.wiff SUBJECT_SAMPLE_FACTORS 2854 EicoT47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT47.wiff SUBJECT_SAMPLE_FACTORS 3024 EicoT48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT48.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoT49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT49.wiff SUBJECT_SAMPLE_FACTORS 3102 EicoT50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT50.wiff SUBJECT_SAMPLE_FACTORS 3104 EicoT51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT51.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoT52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT52.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoT53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT53.wiff SUBJECT_SAMPLE_FACTORS 2844 EicoT54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT54.wiff SUBJECT_SAMPLE_FACTORS 2845 EicoT55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT55.wiff SUBJECT_SAMPLE_FACTORS 2846 EicoT56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT56.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-P1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P1.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-P2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P2.wiff SUBJECT_SAMPLE_FACTORS 2442 TFA-P3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P3.wiff SUBJECT_SAMPLE_FACTORS 2440 TFA-P4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P4.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-P5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P5.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-P6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P6.wiff SUBJECT_SAMPLE_FACTORS 3190 TFA-P7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P7.wiff SUBJECT_SAMPLE_FACTORS 2165 TFA-P8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P8.wiff SUBJECT_SAMPLE_FACTORS 2167 TFA-P9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P9.wiff SUBJECT_SAMPLE_FACTORS 2168 TFA-P10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P10.wiff SUBJECT_SAMPLE_FACTORS 2333 TFA-P11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P11.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-P12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P12.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-P13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P13.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-P14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P14.wiff SUBJECT_SAMPLE_FACTORS 2264 TFA-P15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P15.wiff SUBJECT_SAMPLE_FACTORS 2267 TFA-P16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P16.wiff SUBJECT_SAMPLE_FACTORS 2265 TFA-P17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P17.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-P18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P18.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-P19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P19.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-P20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P20.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-P21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P21.wiff SUBJECT_SAMPLE_FACTORS 2170 TFA-P22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P22.wiff SUBJECT_SAMPLE_FACTORS 2169 TFA-P23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P23.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-P24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P24.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-P25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P25.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-P26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P26.wiff SUBJECT_SAMPLE_FACTORS 2284 TFA-P27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-P28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-P29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-P30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P30.wiff SUBJECT_SAMPLE_FACTORS 2352 TFA-P31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P31.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-P32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P32.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-P33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P33.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-P34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P34.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-P35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P35.wiff SUBJECT_SAMPLE_FACTORS 2171 TFA-P36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P36.wiff SUBJECT_SAMPLE_FACTORS 2174 TFA-P37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P37.wiff SUBJECT_SAMPLE_FACTORS 2175 TFA-P38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P38.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-P39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P39.wiff SUBJECT_SAMPLE_FACTORS 2387 TFA-P40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P40.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-P41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P41.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-P42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P42.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-P43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P43.wiff SUBJECT_SAMPLE_FACTORS 2394 TFA-P44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P44.wiff SUBJECT_SAMPLE_FACTORS 2398 TFA-P45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P45.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-P46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P46.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-P47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P47.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-P48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P48.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-P49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P49.wiff SUBJECT_SAMPLE_FACTORS 2177 TFA-P50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P50.wiff SUBJECT_SAMPLE_FACTORS 2180 TFA-P51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P51.wiff SUBJECT_SAMPLE_FACTORS 2384 TFA-P52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P52.wiff SUBJECT_SAMPLE_FACTORS 2389 TFA-P53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P53.wiff SUBJECT_SAMPLE_FACTORS 2391 TFA-P54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P54.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-P55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P55.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-P56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P56.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoP1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP1.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoP2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP2.wiff SUBJECT_SAMPLE_FACTORS 2442 EicoP3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP3.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoP4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP4.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoP5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP5.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoP6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP6.wiff SUBJECT_SAMPLE_FACTORS 3190 EicoP7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP7.wiff SUBJECT_SAMPLE_FACTORS 2165 EicoP8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP8.wiff SUBJECT_SAMPLE_FACTORS 2167 EicoP9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP9.wiff SUBJECT_SAMPLE_FACTORS 2168 EicoP10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP10.wiff SUBJECT_SAMPLE_FACTORS 2333 EicoP11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP11.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoP12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP12.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoP13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP13.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoP14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP14.wiff SUBJECT_SAMPLE_FACTORS 2264 EicoP15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP15.wiff SUBJECT_SAMPLE_FACTORS 2267 EicoP16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP16.wiff SUBJECT_SAMPLE_FACTORS 2265 EicoP17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP17.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoP18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP18.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoP19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP19.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoP20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP20.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoP21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP21.wiff SUBJECT_SAMPLE_FACTORS 2170 EicoP22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP22.wiff SUBJECT_SAMPLE_FACTORS 2169 EicoP23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP23.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoP24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP24.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoP25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP25.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoP26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP26.wiff SUBJECT_SAMPLE_FACTORS 2284 EicoP27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoP28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoP29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoP30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP30.wiff SUBJECT_SAMPLE_FACTORS 2352 EicoP31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP31.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoP32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP32.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoP33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP33.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoP34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP34.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoP35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP35.wiff SUBJECT_SAMPLE_FACTORS 2171 EicoP36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP36.wiff SUBJECT_SAMPLE_FACTORS 2174 EicoP37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP37.wiff SUBJECT_SAMPLE_FACTORS 2175 EicoP38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP38.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoP39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP39.wiff SUBJECT_SAMPLE_FACTORS 2387 EicoP40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP40.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoP41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP41.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoP42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP42.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoP43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP43.wiff SUBJECT_SAMPLE_FACTORS 2394 EicoP44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP44.wiff SUBJECT_SAMPLE_FACTORS 2398 EicoP45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP45.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoP46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP46.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoP47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP47.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoP48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP48.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoP49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP49.wiff SUBJECT_SAMPLE_FACTORS 2177 EicoP50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP50.wiff SUBJECT_SAMPLE_FACTORS 2180 EicoP51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP51.wiff SUBJECT_SAMPLE_FACTORS 2384 EicoP52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP52.wiff SUBJECT_SAMPLE_FACTORS 2389 EicoP53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP53.wiff SUBJECT_SAMPLE_FACTORS 2391 EicoP54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP54.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoP55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP55.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoP56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP56.wiff #COLLECTION CO:COLLECTION_SUMMARY Animals were sacrificed by CO2 narcosis, and large intestines were excised, CO:COLLECTION_SUMMARY washed with ice-cold PBS, and laid flat on filter paper. Tumor-adjacent CO:COLLECTION_SUMMARY full-thickness colon segments were flash-frozen in liquid Nitrogen and stored at CO:COLLECTION_SUMMARY -80C until analysis. Blood was collected via cardiac puncture and put in lithium CO:COLLECTION_SUMMARY heparin tubes on ice. Samples were centrifuged at 2,000 g for 20 minutes, and CO:COLLECTION_SUMMARY supernatant (plasma) was collected and stored at -80C until analysis. CO:SAMPLE_TYPE Blood (Plasma) and Large Intestine #TREATMENT TR:TREATMENT_SUMMARY Rats were fed two doses of TP-252 equivalent to consuming 1.3 and 2.6 g/kg/day TR:TREATMENT_SUMMARY for LD TP-252 and HD TP-252, respectively. Alternatively, rats were also fed a TR:TREATMENT_SUMMARY diet containing 2% EPA-FFA in their diet (equivalent to 1.14 g/kg/day of EPA). TR:TREATMENT_SUMMARY In groups receiving naproxen, the dose of naproxen was 11.4 mg/kg/day, or TR:TREATMENT_SUMMARY roughly 4 mg/rat/day. These treatment groups were carried out for the 20 weeks, TR:TREATMENT_SUMMARY and then animals were sacrificed and tissue collected and analyzed. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples (0.85 ml) were spiked with 5 ng each (in 150 μl methanol) of SP:SAMPLEPREP_SUMMARY 15(S)-HETE-d8,14(15)-EpETrE-d11, Resolvin D2-d5, Leukotriene B4-d4, and SP:SAMPLEPREP_SUMMARY Prostaglandin E1-d4 as internal standards for recovery and quantitation and SP:SAMPLEPREP_SUMMARY mixed thoroughly. The samples were then extracted for PUFA metabolites using C18 SP:SAMPLEPREP_SUMMARY extraction columns as described earlier [1-4]. Briefly, the internal standard SP:SAMPLEPREP_SUMMARY spiked samples were applied to conditioned C18 cartridges, washed with 15% SP:SAMPLEPREP_SUMMARY methanol in water followed by hexane and dried under vacuum. The cartridges were SP:SAMPLEPREP_SUMMARY eluted with 0.5 ml methanol. The eluate was dried under a gentle stream of SP:SAMPLEPREP_SUMMARY nitrogen. The residue was redissolved in 50 μl methanol-25 mM aqueous ammonium SP:SAMPLEPREP_SUMMARY acetate (1:1) and subjected to LC-MS analysis. SP:SAMPLEPREP_PROTOCOL_FILENAME Methods of Eicosanoid Detection.pdf #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3μ, CH:CHROMATOGRAPHY_SUMMARY 2.1x150 mm) column. The mobile phase consisted of a gradient between A: CH:CHROMATOGRAPHY_SUMMARY methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile CH:CHROMATOGRAPHY_SUMMARY (90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with CH:CHROMATOGRAPHY_SUMMARY respect to the composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%; CH:CHROMATOGRAPHY_SUMMARY 8-15 min, 80-95%; and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC CH:CHROMATOGRAPHY_SUMMARY eluate was directly introduced to ESI source of QTRAP5500 mass analyzer CH:CHROMATOGRAPHY_SUMMARY (ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35 CH:CHROMATOGRAPHY_SUMMARY psi, GS1: 35 psi, GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V, CH:CHROMATOGRAPHY_SUMMARY Collision gas: low, Declustering Potential: -60 V, and Entrance Potential: -7 V. CH:CHROMATOGRAPHY_SUMMARY The eluate was monitored by Multiple Reaction Monitoring method to detect unique CH:CHROMATOGRAPHY_SUMMARY molecular ion – daughter ion combinations for each of the lipid mediators CH:CHROMATOGRAPHY_SUMMARY using a scheduled MRM around the expected retention time for each compound. CH:CHROMATOGRAPHY_SUMMARY Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials CH:CHROMATOGRAPHY_SUMMARY (7 – 10 V) were used for each MRM transition. Spectra of each peak detected in CH:CHROMATOGRAPHY_SUMMARY the scheduled MRM were recorded using Enhanced Product Ion scan to confirm the CH:CHROMATOGRAPHY_SUMMARY structural identity. The data was collected using Analyst 1.6.2 software and the CH:CHROMATOGRAPHY_SUMMARY MRM transition chromatograms were quantitated by MultiQuant software (both from CH:CHROMATOGRAPHY_SUMMARY ABSCIEX). The internal standard signals in each chromatogram were used for CH:CHROMATOGRAPHY_SUMMARY normalization, recovery, as well as relative quantitation of each analyte. CH:CHROMATOGRAPHY_TYPE None (Direct infusion) CH:INSTRUMENT_NAME Prominence XR CH:COLUMN_NAME Targa C8, 2x10 mm, 5μ CH:FLOW_RATE 0.25ml/min #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME ABI Sciex 5500 QTrap MS:INSTRUMENT_TYPE QTRAP MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS Mass spectra for each detected lipid metabolite were recorded using the enhanced MS:MS_COMMENTS production feature to verify the identity of the detected peak. Data were MS:MS_COMMENTS collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX) MS:MS_COMMENTS software, respectively. Correction for recovery efficiencies and relative MS:MS_COMMENTS quantitation of each analyte were performed using signals from each chromatogram MS:MS_COMMENTS corresponding to the spiked-in internal standards. Under standardized conditions MS:MS_COMMENTS of liquid chromatography-mass spectrometry quantitation, the detection limits MS:MS_COMMENTS for the eicosanoids are 1–2 pg on the column and the limit of quantitation is MS:MS_COMMENTS 5 pg at a signal-to-noise ratio of 3. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS mg/g tissue MS_METABOLITE_DATA_START Samples TFA-T1 TFA-T2 TFA-T3 TFA-T4 TFA-T5 TFA-T6 TFA-T7 TFA-T8 TFA-T9 TFA-T10 TFA-T11 TFA-T12 TFA-T13 TFA-T14 TFA-T15 TFA-T16 TFA-T17 TFA-T18 TFA-T19 TFA-T20 TFA-T21 TFA-T22 TFA-T23 TFA-T24 TFA-T25 TFA-T26 TFA-T27 TFA-T28 TFA-T29 TFA-T30 TFA-T31 TFA-T32 TFA-T33 TFA-T34 TFA-T35 TFA-T36 TFA-T37 TFA-T38 TFA-T39 TFA-T40 TFA-T41 TFA-T42 TFA-T43 TFA-T44 TFA-T45 TFA-T46 TFA-T47 TFA-T48 TFA-T49 TFA-T50 TFA-T51 TFA-T52 TFA-T53 TFA-T54 TFA-T55 TFA-T56 Factors Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon Dodecanoic acid 2.157 6.899 6.831 5.501 5.821 7.518 4.719 3.219 2.531 8.370 5.623 4.350 5.380 2.970 3.830 Myristic acid 1.042 2.527 2.528 1.848 0.608 0.772 0.939 0.647 0.470 0.487 3.548 0.500 1.249 1.613 0.886 1.444 12.528 23.245 4.476 3.640 1.611 1.056 5.016 1.083 2.073 0.774 24.361 2.240 3.165 4.834 2.008 2.416 2.799 1.417 0.755 6.736 3.724 3.009 1.757 7.652 3.219 4.648 4.543 2.140 5.248 3.728 6.469 2.815 3.169 4.380 2.404 7.150 2.017 2.847 2.118 0.836 Pentadecanoic acid 1.489 2.476 2.810 2.048 0.889 1.046 1.210 0.969 0.867 0.624 3.415 0.770 1.555 2.312 0.935 1.491 4.642 4.011 1.939 3.495 3.002 1.193 2.905 1.130 1.879 1.069 3.938 1.338 2.265 1.720 2.024 2.224 2.631 1.250 0.948 3.737 3.366 2.557 1.580 2.847 2.676 3.810 1.907 2.375 2.939 2.551 1.663 2.732 1.446 3.498 1.770 3.813 1.937 2.319 1.694 0.834 Palmitoleic acid 0.834 15.917 3.702 4.987 1.173 1.264 2.758 1.682 1.463 0.576 5.541 1.230 2.651 1.235 2.364 3.208 43.991 149.808 20.323 6.189 2.675 5.334 12.019 3.838 2.042 5.641 185.366 10.174 6.099 21.958 3.833 5.513 5.399 6.045 7.857 50.509 16.158 6.308 8.396 23.966 7.213 8.179 9.939 5.909 14.582 10.297 49.989 5.494 19.192 11.074 2.662 17.471 3.383 7.328 4.897 3.191 Palmitic acid 23.785 58.888 21.633 20.460 18.666 16.625 27.798 12.143 11.775 10.110 35.318 13.591 21.423 14.024 14.687 18.128 90.613 122.239 35.554 36.246 13.504 30.785 41.031 18.870 15.989 17.134 136.386 20.129 30.523 47.291 23.453 27.598 29.857 29.526 18.430 48.765 34.759 28.301 33.634 72.351 35.103 36.241 37.315 18.995 46.082 33.188 54.418 32.366 26.534 33.630 20.422 47.577 20.820 23.165 18.212 18.872 Heptadecenoic acid 0.135 0.744 0.225 0.237 0.142 0.150 0.231 0.130 0.132 0.087 0.350 0.125 0.241 0.126 0.181 0.218 0.988 2.984 0.432 0.396 0.200 0.322 0.379 0.191 0.126 0.169 3.630 0.209 0.264 0.606 0.244 0.305 0.344 0.273 0.274 1.277 0.689 0.261 0.372 0.908 0.381 0.429 0.288 0.233 0.527 0.296 0.561 0.341 0.249 0.390 0.206 0.541 0.234 0.205 0.155 0.152 Heptadecanoic acid 1.725 3.373 1.547 1.357 1.205 1.190 1.807 0.870 0.796 0.864 2.566 0.915 1.435 1.014 1.247 1.428 4.147 6.291 1.841 1.947 0.992 2.460 2.175 1.208 0.942 1.092 5.117 0.870 1.721 2.231 1.407 1.621 2.130 1.502 1.289 2.988 2.362 1.845 1.734 3.778 2.259 2.287 2.031 1.081 2.564 1.631 1.990 1.853 1.142 1.853 1.210 2.632 1.341 1.154 0.974 1.055 Octadecatetraenoic acid (Stearidonic acid) 0.021 0.034 0.000 0.002 Linolenic acid (alpha) 0.136 0.062 0.057 0.094 0.089 0.200 0.691 0.081 0.080 0.051 0.086 0.050 0.059 0.374 0.045 0.065 0.087 0.047 0.062 0.079 0.066 0.068 0.108 0.080 0.084 0.062 0.140 0.074 0.087 0.047 0.098 0.057 0.090 0.050 0.067 0.060 0.045 Linoleic acid 12.012 167.981 38.689 55.893 19.930 13.370 43.769 19.838 13.609 7.824 72.552 6.467 27.164 14.892 13.897 20.431 221.790 465.208 71.728 59.251 21.827 29.572 68.425 26.477 20.789 16.210 332.320 25.585 43.563 103.103 26.062 45.875 44.326 54.680 40.417 117.884 62.070 29.026 33.884 160.859 55.521 44.515 76.376 30.562 75.924 49.940 94.300 18.919 40.035 36.042 12.999 97.380 15.301 26.459 26.193 15.466 Oleic acid 10.961 95.214 22.174 27.568 11.907 7.921 26.293 10.560 8.963 5.280 41.652 6.695 17.189 8.749 9.414 11.796 119.356 313.361 28.662 26.425 10.908 20.207 38.690 17.348 9.832 9.641 320.959 13.206 24.177 65.220 16.556 25.152 29.031 29.911 23.623 65.119 32.083 15.745 20.268 75.920 31.595 29.577 30.806 16.327 42.566 37.193 56.276 17.383 23.813 26.661 8.350 57.314 14.602 15.093 10.506 8.486 Stearic acid 71.887 80.485 36.010 28.652 48.314 53.740 68.856 32.555 37.356 40.172 63.717 40.628 55.624 44.868 45.830 48.846 71.521 68.215 65.981 62.664 33.540 85.077 62.770 36.771 32.430 31.096 71.217 28.440 52.676 40.333 52.804 54.331 75.587 44.773 47.678 63.418 72.462 50.426 72.956 66.759 58.069 69.961 43.341 35.552 55.099 45.242 41.187 73.332 28.684 51.124 44.564 48.248 40.768 37.750 37.405 51.428 Eicosapentaenoic acid 0.098 0.115 0.076 0.065 0.092 0.099 0.101 0.074 0.067 0.091 0.124 0.069 0.110 0.075 0.207 0.285 0.892 5.096 0.422 0.373 0.197 1.154 0.981 0.811 0.342 0.406 6.751 0.419 0.578 0.743 0.319 0.369 0.586 0.447 0.380 1.679 1.184 0.691 0.837 3.303 1.207 0.927 0.516 0.305 0.674 0.579 0.716 0.271 0.361 0.350 0.189 0.928 0.380 0.340 0.257 0.316 Arachidonic acid 1.380 2.842 1.284 1.597 1.238 0.777 2.106 0.986 1.112 0.718 2.504 0.882 2.213 0.957 0.541 0.749 1.126 1.811 0.886 1.104 0.816 0.764 0.471 0.592 0.403 0.374 1.096 0.393 1.241 1.209 1.753 1.651 2.096 0.937 1.210 1.454 1.093 0.772 1.090 1.230 1.173 0.999 0.379 0.846 0.867 0.632 1.203 1.413 0.634 1.053 0.719 1.267 1.088 0.760 0.707 0.620 Dihomo-g-linolenic acid 0.182 0.053 0.094 0.045 0.104 0.031 0.052 0.105 0.054 0.103 0.002 0.004 0.033 0.096 0.037 0.034 0.031 0.013 0.052 0.004 0.046 0.061 0.083 0.096 0.053 0.024 0.058 0.059 0.032 0.006 0.041 0.038 0.049 0.018 0.023 0.010 0.025 0.057 0.062 0.019 0.034 0.003 0.084 0.052 0.022 0.022 Mead acid 0.090 0.072 0.057 0.040 0.040 0.021 0.054 0.022 0.054 0.023 0.026 0.037 0.052 0.142 0.022 0.043 0.029 0.061 0.037 0.036 0.028 0.027 0.121 0.022 0.056 0.047 0.047 0.057 0.094 0.045 0.046 0.053 0.048 0.046 0.038 0.083 0.056 0.059 0.026 0.036 0.034 0.039 0.033 0.055 0.022 0.043 0.028 0.049 0.040 0.034 0.020 Eicosadienoic acid 1.357 2.030 0.994 1.407 0.997 0.512 1.066 0.457 0.362 0.351 1.755 0.281 0.999 0.371 0.337 0.498 1.452 3.052 0.412 0.813 0.454 0.743 0.633 0.685 0.311 0.231 2.411 0.280 1.516 1.075 0.631 0.773 0.995 0.870 0.676 0.936 0.817 0.452 0.529 1.614 0.907 0.686 0.321 0.418 0.496 0.589 0.596 0.326 0.321 0.525 0.335 1.183 0.326 0.436 0.378 0.293 Eicosenoic acid 0.660 2.799 0.783 0.943 0.680 0.471 1.042 0.368 0.340 0.321 1.406 0.386 0.757 0.380 0.438 0.528 2.663 15.851 0.412 0.806 0.366 0.757 0.945 0.709 0.354 0.326 11.846 0.339 1.057 1.658 0.597 0.798 1.168 0.948 0.789 1.928 1.309 0.566 0.689 2.276 1.065 0.878 0.813 0.525 0.934 0.924 0.720 0.612 0.408 0.793 0.376 1.543 0.545 0.497 0.346 0.396 Arachidic acid 3.363 5.089 3.533 2.378 3.054 3.216 4.021 1.615 1.487 2.025 4.403 2.008 3.159 2.174 2.334 2.777 4.937 9.389 2.223 3.827 1.904 5.209 3.238 2.348 1.747 1.839 7.550 1.293 3.097 2.669 2.272 2.492 4.440 3.247 2.694 4.047 3.977 2.576 2.768 4.304 3.454 3.503 2.280 1.861 2.776 2.922 1.842 2.881 1.422 2.659 1.901 3.040 2.207 1.922 1.664 2.393 Docosahexaenoic acid 0.279 0.614 0.247 0.359 0.279 0.162 0.427 0.177 0.212 0.122 0.504 0.150 0.393 0.153 0.128 0.206 0.709 1.746 0.781 0.265 0.269 0.329 0.302 0.228 0.158 0.116 1.767 0.152 0.342 0.449 0.386 0.417 0.492 0.303 0.315 0.977 0.523 0.272 0.321 0.774 0.449 0.387 0.224 0.244 0.387 0.324 0.895 0.341 0.224 0.330 0.202 0.544 0.289 0.172 0.515 0.183 Docosapentaenoic acid (n-3) 0.038 0.054 0.027 0.028 0.030 0.024 0.039 0.026 0.027 0.051 0.024 0.045 0.027 0.059 0.095 0.284 1.000 0.172 0.103 0.084 0.196 0.205 0.181 0.101 0.089 1.022 0.100 0.180 0.209 0.159 0.165 0.222 0.137 0.147 0.394 0.245 0.162 0.215 0.509 0.266 0.220 0.096 0.099 0.172 0.137 0.268 0.114 0.103 0.117 0.066 0.230 0.129 0.109 0.129 0.082 Docosapentaenoic acid (n-6) 0.060 0.062 0.035 0.042 0.043 0.057 0.034 0.035 0.029 0.062 0.033 0.058 0.029 Docosatetraenoic acid 0.198 0.229 0.116 0.162 0.134 0.091 0.245 0.120 0.156 0.076 0.255 0.101 0.238 0.092 0.032 0.040 0.050 0.179 0.012 0.040 0.050 0.022 0.011 0.018 0.012 0.006 0.059 0.009 0.058 0.055 0.097 0.103 0.131 0.051 0.076 0.051 0.040 0.034 0.042 0.034 0.041 0.035 0.007 0.040 0.031 0.028 0.045 0.065 0.026 0.057 0.035 0.056 0.050 0.032 0.013 0.020 Docosatrienoic acid 0.140 0.143 0.100 0.084 0.069 0.078 0.074 0.064 0.060 0.058 0.110 0.054 0.121 0.047 0.036 0.050 0.045 0.063 0.013 0.049 0.033 0.045 0.024 0.025 0.025 0.020 0.055 0.022 0.062 0.035 0.054 0.062 0.083 0.044 0.058 0.043 0.047 0.037 0.039 0.055 0.045 0.043 0.014 0.036 0.030 0.025 0.031 0.042 0.023 0.045 0.044 0.034 0.027 0.037 0.022 0.033 Docosadienoic acid 0.063 0.086 0.047 0.051 0.053 0.041 0.059 0.029 0.024 0.035 0.084 0.030 0.054 0.027 0.027 0.041 0.039 0.056 0.014 0.037 0.021 0.043 0.026 0.030 0.024 0.016 0.055 0.015 0.060 0.031 0.028 0.046 0.051 0.032 0.038 0.032 0.036 0.028 0.033 0.052 0.036 0.054 0.019 0.021 0.025 0.026 0.019 0.025 0.016 0.028 0.030 0.041 0.024 0.027 0.019 0.027 Docosenoic acid 3.374 4.650 2.406 1.169 1.829 1.778 5.266 1.014 0.980 1.428 5.642 1.944 1.784 1.748 1.891 3.444 2.931 4.981 3.231 2.595 1.044 6.135 2.011 2.374 2.189 1.229 4.335 1.186 3.615 1.705 2.120 6.720 3.855 1.563 2.941 5.985 5.470 3.190 5.904 3.136 1.874 9.013 3.500 1.375 2.494 4.886 1.568 3.459 1.732 2.953 2.537 5.500 4.219 2.313 1.211 1.860 Docosanoic acid (Behenic acid) 1.385 5.108 2.806 1.875 1.875 1.915 2.839 1.021 0.898 0.963 3.315 1.316 2.481 1.361 1.431 2.097 3.875 6.383 1.284 4.216 1.452 5.833 2.603 1.947 1.158 1.413 6.333 1.198 2.832 3.034 3.111 2.947 5.078 2.995 2.503 5.447 4.876 2.322 3.212 5.395 3.761 4.149 1.435 1.651 2.027 3.074 1.635 1.922 1.237 2.691 1.210 5.337 2.327 1.863 1.124 1.529 Nervonic acid 0.322 2.279 0.624 0.607 0.552 0.391 0.755 0.288 0.291 0.260 1.077 0.327 0.616 0.332 0.401 0.625 2.045 6.631 0.402 0.899 0.291 1.073 0.875 0.557 0.320 0.540 6.044 0.514 0.868 1.248 0.729 0.898 1.275 0.743 0.773 5.332 2.618 0.664 1.024 2.165 1.110 1.315 0.694 0.489 0.822 0.987 0.623 0.619 0.347 0.817 0.417 2.132 0.589 0.673 0.266 0.416 Lignoceric acid 1.637 3.543 1.735 1.289 1.347 1.407 1.955 0.828 0.893 0.790 2.192 1.106 1.697 0.849 1.358 1.596 2.883 4.274 1.481 2.467 1.011 3.816 2.094 1.496 0.969 1.036 5.071 1.016 1.957 2.083 2.004 2.108 3.761 1.949 1.943 7.930 4.539 2.099 2.577 4.222 2.887 3.058 1.159 1.363 1.871 2.114 1.413 1.731 0.964 2.302 1.283 3.729 1.622 1.416 0.978 1.546 Hexacosenoic acid 0.015 0.148 0.027 0.029 0.010 0.038 0.004 0.018 0.045 0.012 0.014 0.010 0.021 0.025 0.259 1.294 0.032 0.057 0.007 0.062 0.078 0.043 0.017 0.031 1.194 0.039 0.060 0.119 0.045 0.053 0.072 0.040 0.040 1.337 0.536 0.043 0.088 0.231 0.101 0.055 0.048 0.088 0.060 0.040 0.039 0.019 0.039 0.022 0.174 0.026 0.027 0.018 0.017 Hexacosanoic acid 0.408 0.553 0.146 0.111 0.166 0.269 0.337 0.123 0.173 0.144 0.221 0.217 0.195 0.116 0.444 0.218 0.411 0.483 0.475 0.251 0.121 0.400 0.224 0.147 0.122 0.155 0.439 0.130 0.167 0.158 0.219 0.215 0.470 0.173 0.241 1.317 0.620 0.351 0.296 0.350 0.286 0.376 0.292 0.196 0.436 0.247 0.173 0.288 0.173 0.314 0.272 0.328 0.173 0.167 0.178 0.341 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name KEGG ID PubChem ID quantified m/z Dodecanoic acid C02679 3893 200 Myristic acid C06242 11005 228 Pentadecanoic acid C16537 13849 242 Palmitoleic acid C08362 445638 254 Palmitic acid C00249 985 256 Heptadecenoic acid C16536 5312440 268 Heptadecanoic acid 10465 270 Octadecatetraenoic acid (Stearidonic acid) C16300 5312508 276 Linolenic acid (alpha) C06427 8662 278 Linoleic acid C01595 5280450 280 Oleic acid C00712 3978 282 Stearic acid C01530 4692 284 Eicosapentaenoic acid C06428 446284 302 Arachidonic acid C00219 444899 304 Dihomo-g-linolenic acid C03242 53486 306 Mead acid C21938 5312531 306 Eicosadienoic acid C16525 5282805 308 Eicosenoic acid C16526 5282768 310 Arachidic acid C06425 10467 312 Docosahexaenoic acid C06429 445580 328 Docosapentaenoic acid (n-3) C16513 5497182 330 Docosapentaenoic acid (n-6) 5282848 330 Docosatetraenoic acid C16527 5497181 332 Docosatrienoic acid C16534 5312557 334 Docosadienoic acid C16533 51090862 336 Docosenoic acid C08316 10514 338 Docosanoic acid (Behenic acid) C08281 10479 340 Nervonic acid C08323 10521 366 Lignoceric acid C08320 10518 368 Hexacosenoic acid C17278 5282775 394 Hexacosanoic acid C21931 10469 396 METABOLITES_END #END